Valuation: Black Diamond Therapeutics, Inc.

Market Cap 10Cr 8.78Cr 8.1Cr 7.56Cr 14Cr 948.15Cr 14Cr 97Cr 38Cr 467.88Cr 38Cr 37Cr 1.63TCr P/E 2026 *
-2.7x
P/E 2027 * -1.74x
Enterprise Value 10Cr 8.78Cr 8.1Cr 7.56Cr 14Cr 948.15Cr 14Cr 97Cr 38Cr 467.88Cr 38Cr 37Cr 1.63TCr EV / Sales 2026 *
18.1x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
1 day+4.86%
1 week+13.35%
Current month-17.79%
1 month-19.25%
3 months-10.10%
6 months-26.71%
Current year-24.90%
1 week 1.61
Extreme 1.61
1.92
1 month 1.6
Extreme 1.6
2.31
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
12.48
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 16/09/2023
Chief Tech/Sci/R&D Officer 51 11/08/2021
Director of Finance/CFO 41 07/10/2024
Director TitleAgeSince
Director/Board Member 61 01/03/2017
Director/Board Member 47 01/12/2019
Director/Board Member 50 01/12/2018
Date Insider Type Main position Quantity % Market Cap.
19/06Free

Director

8,961 0.0156%
19/06
NEA Management Co. LLC
OtherCompany 0 0%
19/06Free

Director

7,907 0.0138%
Change 5-day change 1-year change 3-year change Capi.($)
+4.86%+13.35%-26.41%-63.86% 10Cr
+3.31%-0.20%+72.71%+128.31% 5.58TCr
-1.32%+16.55%+89.14%+101.41% 5.57TCr
-0.66%+3.16%-12.20%-13.39% 2.38TCr
+3.19%+5.16%+6.74%+409.10% 2.27TCr
+4.45%+5.06%+36.50%-30.43% 1.61TCr
+0.62%+6.42%+23.96%+185.90% 1.36TCr
+5.51%+22.37%+171.85%+333.54% 1.48TCr
+0.92%+3.76%+76.03%+130.63% 1.22TCr
-2.10%+6.95%+158.99%+162.32% 1.18TCr
Average +1.86%+6.41%+59.73%+134.35% 2.27TCr
Weighted average by Cap. +1.38%+5.02%+66.81%+142.32%

Financials

2026 *2027 *
Net sales 55.56L 48.63L 44.89L 41.87L 78.89L 53Cr 80.31L 5.38Cr 2.09Cr 26Cr 2.09Cr 2.04Cr 90Cr -
Net income -4.05Cr -3.54Cr -3.27Cr -3.05Cr -5.75Cr -382.68Cr -5.85Cr -39Cr -15Cr -188.84Cr -15Cr -15Cr -657.87Cr -7Cr -6.13Cr -5.66Cr -5.28Cr -9.95Cr -662.29Cr -10Cr -68Cr -26Cr -326.81Cr -26Cr -26Cr -1.14TCr
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
30/26/30 $1.830 +4.57% 9,00,598
29/26/29 $1.750 +2.34% 11,54,453
26/26/26 $1.710 +0.59% 85,78,830
25/26/25 $1.700 -8.60% 19,32,360
24/26/24 $1.860 +15.53% 28,71,541
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.750USD
Average target price
9.857USD
Spread / Average Target
+463.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock